"Turbulent market" leads Vascular Solutions to delay IPO (initial public offering)
This article was originally published in Clinica
Vascular Solutions has postponed its initial public offering, citing the "turbulent condition of the stock market". The US company, which makes the Duett arterial puncture site sealing device, says that it will re-evaluate the condition of the stock market for IPOs in January.
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.